Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value..作者：Jiang, Y. Z., Liu, Y. R., Xu, X. E., Jin, X., Hu, X., Yu, K. D., and Shao, Z. M. (2016). Cancer Res. 2016 Apr 15;76(8):2105-14（IF=9.13） Enriched variations in TEKT4 and breast cancer resistance to paclitaxel.作者：Jiang YZ, Yu KD, Peng WT, Di GH, Wu J, Liu GY, Shao ZM. Nat Commun. 2014 May 13;5:3802（IF=12.353） Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.作者：Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X, Shao ZM. Nat Commun. 2018 Apr 10;9(1):1357.（IF=12.353） Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.作者：Zuo WJ, Jiang YZ, Wang YJ, Xu XE, Hu X, Liu GY, Wu J, Di GH, Yu KD, Shao ZM. Clin Cancer Res. 2016 Oct 1;22(19):4859-4869.（IF=10.199） Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.作者：Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD, Shao ZM. Clin Cancer Res. 2016 Apr 1;22(7):1653-62. .（IF=10.199） Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.作者：Jiang YZ, Yu KD, Bao J, Peng WT, Shao ZM. Cancer Res. 2014 Jul 1;74(13):3399-407..（IF=9.13） Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.作者：Ye FG, Song CG, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L, Hu X, Shao ZM. Cancer Res. 2015 Apr 1;75(7):1504-15.（IF=9.13） PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression.作者：Zheng YZ, Xue MZ, Shen HJ, Li XG, Ma D, Gong Y, Liu YR, Qiao F, Xie HY, Lian B, Sun WL, Zhao HY, Yao L, Zuo WJ, Li DQ, Wang P, Hu X, Shao ZM. Cancer Res. 2018 Jun 15;78(12):3190-3206.（IF=9.13） Molecular essence and endocrine responsiceness of estrogen receptor-negative, progesterone receptor-positive and HER2-negative breast cancer.作者：Yu KD, Jiang YZ, Hao S, Shao ZM. BMC Med. 2015 Oct 5;13:254.（IF=9.088） Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.作者：Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Lancet Oncol. 2015 Apr;16(4):436-46.（IF=36.418） Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.作者：Yi-Zhou Jiang, Ding Ma, Chen Suo, Jinxiu Shi, Mengzhu Xue, Xin Hu, Yi Xiao, Ke-Da Yu,Yi-Rong Liu,Ying Yu,Yuanting Zheng, Xiangnan Li, Chenhui Zhang, Pengchen Hu, Jing Zhang, Qi Hua,Jiyang Zhang, Wanwan Hou,Luyao Ren, Ding Bao, Bingying Li, Jingcheng Yang,Ling Yao,Wen-Jia Zuo,Shen Zhao, Yue Gong,Yi-Xing Ren,Ya-Xin Zhao,Yun-Song Yang,Zhenmin Niu, Zhi-Gang Cao, Daniel G.Stover, Claire Verschraegen,Virginia Kaklamani,Anneleen Daemen, John R. Benson, Kazuaki Takabe,Fan Bai, Da-Qiang Li, Peng Wang, Leming Shi, Wei Huang, and Zhi-Ming Shao. Cancer Cell. 2019 Mar 18;35(3):428-440（IF=22.844） The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation.作者：Xi Jin, Xiao-En Xu, Yi-Zhou Jiang, Yi-Rong Liu, Wei Sun, Ya-Jie Guo, Yi-Xing Ren, Wen-Jia Zuo, Xin Hu, Sheng-Lin Huang, Hong-Jie Shen, Fei Lan, Yun-Fei He, Guo-Hong Hu, Gen-Hong Di, Xiang-Huo He, Da-Qiang Li, Suling Liu, Ke-Da Yu, Zhi-Ming Shao.Sci Adv. 2019 Mar; 5(3): eaat9820. Published online 2019 Mar 6. （IF=11.511） Multi-omics profiling reveals distinct microenvironment characterization and suggests immuneescape mechanisms of triple-negative breast cancer.作者：Xiao Y, Ma D, Zhao S, Suo C, Shi J, Xue MZ, Ruan M, Wang H, Zhao J, Li Q, Wang P, Shi L, Yang WT, Huang W, Hu X, Yu K, Huang S, Bertucci F, Jiang YZ, Shao ZM. Clin Cancer Res. 2019 Mar 5. pii: clincanres.3524.2018. doi: 10.1158/1078-0432.CCR-18-3524. [Epub ahead of print]. （IF=10.199）